Market Insight - German pharma positive it will ride out economic storm
This article was originally published in Scrip
Executive Summary
Hamstrung by health reforms, Germany's research-based pharmaceutical industry is crying out for less regulation so it can get back to the job of delivering innovation. A rethink of the policies designed to promote competition and fresh incentives for investment in biotech would also help push industry in the right direction. At the same time, German authorities need to take control of the country's finances, argues Faraz Kermani.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.